Evaluating Safety and Efficacy of Herbal Treatment in Ulcerative Colitis

NCT ID: NCT02442960

Last Updated: 2020-11-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-12-31
• Study Completion Date: 2017-07-26

Brief Summary

This is a 12-week, open-label, dose-escalation Phase 1b study of a herbal treatment given orally to subjects with ulcerative colitis. Subjects will be sequentially enrolled to one of two cohorts in up to two clinical sites. Treatment will be given for 8 weeks and study duration will be 12 weeks.

Detailed Description

This study consists of a 3-month period (12 weeks). You will receive study drug (SA100) for a 2-month period (8weeks) and then will continue to receive study assessements for an additional 1 month (4weeks). During the period in which you receive study drug (SA100), you will be asked to take the study drug twice a day (once in the morning and once in the evening), preferably at the same time each day. You will be assigned to one of three possible treatment groups. The three possible treatment groups are SA100 250 mg, 500 mg, or 750 mg. The group you are assigned to at the start of the study will remain the same throughout the study.

Blood samples, stool (feces), and tissue biopsies (up to 3 per region of colon) will be collected for testing purposes. These samples may also be kept for several years for future research.

An electrocardigram (ECG, which measures the electrical activity in your heart) will be taken at screening and week 2; and a flexible sigmoidoscopy will be performed at screening and week 8, (flexible tube that visualizes your intestine/colon and allows for tissue and stool to be obtained) to confirm your diagnosis of ulcerative colitis, to assess the severity of your disease, and for future testing of your tissue.

Conditions

Ulcerative Colitis

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort 1

Herbal treatment (SA100) 500 mg/day (250 mg twice per day)

Group Type: ACTIVE_COMPARATOR

Herbal treatment (SA100)

Intervention Type: DRUG

This treatment has been used extensively in traditional medicine practices for hundreds of years.

Cohort 2

Herbal treatment (SA100) 1.5 g/day (750 mg twice per day)

Group Type: ACTIVE_COMPARATOR

Herbal treatment (SA100)

Intervention Type: DRUG

This treatment has been used extensively in traditional medicine practices for hundreds of years.

Interventions

Herbal treatment (SA100)

This treatment has been used extensively in traditional medicine practices for hundreds of years.

Intervention Type: DRUG

Other Intervention Names

SA100

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 13 years and ≤ 75 years.

2. Mild, moderate and severe ulcerative colitis (biopsy-proven)

3. Mayo Scoring System Assessment of Ulcerative Colitis Activity score of 3 to 12 at screening.

4. Patients with active disease who are refractory to, intolerant to, or unwilling to take 5-aminosalicylic acid (5-ASA).

5. Patients of age ≥ 13 years and ≤ 17 years with active disease who are refractory or intolerant to 5-aminosalicyclic acid (5-ASA), corticosteroids, small molecule immunomodulators, and biologics or corticosteroid-dependent.

6. Physician's Global Assessment (PGA) Mayo subscore of at least 1 at screening.

7. Endoscopic evidence of active mucosal disease as assessed by flexible sigmoidoscopy with Mayo mucosal appearance subscore of at least 1 at screening.

8. Female patients of child-bearing potential must have a negative serum pregnancy test at the screening visit and agree to use two medically reliable methods of contraception (such as barrier with either spermicide or hormonal contraception) during the study period.

9. Male patients must be willing to use acceptable contraceptive methods and assure that their female partners of child-bearing potential use acceptable contraceptive methods during the study period.

10. Ability to adhere to the study visit schedule and other protocol requirements.

11. Adequate cardiac, renal, and hepatic function as determined by the principal investigators.

12. Written informed consent will be obtained before any study procedure is performed.

Exclusion Criteria

1. Are nursing or pregnant.

2. Patients who are in critical condition

3. Crohn's disease or indeterminate colitis.

4. Known sensitivity to any ingredients in the study drug.

5. A change in therapy within 2 weeks before the baseline visit.

6. Use of immunomodulators (cyclosporine, mercaptopurine, azathioprine, etc.).

7. Diagnosis of diabetes, heart failure, unstable angina, liver or kidney disease, or any other unstable medical condition.

8. Any clinically meaningful laboratory abnormality that in the judgment of the investigator should preclude participation in the study.

9. Impaired renal function (serum creatinine levels >2.0 mg/dL) at screening.

10. Alanine transaminase (ALT) or aspartate transaminase (AST) laboratory values >1.5 times upper limit of normal at screening.

11. Diagnosis of Clostridium difficile, Salmonella, Shigella, Yersinia, Campylobacter, enteropathogenic E. coli in stool.

12. Positive test for hepatitis C virus (HCV) antibody or hepatitis B surface antigen (HBsAg) at screening.

13. Active malignancy (except basal cell carcinoma).

14. Active alcohol or drug abuse.

15. Tobacco smoking within 2 weeks before study entry.

• Minimum Eligible Age: 13 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Stanford University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Berkeley Limketkai, MD

Role: PRINCIPAL_INVESTIGATOR

Stanford University

Locations

Stanford University

Palo Alto, California, United States

Countries

United States

References

Saiki JP, Andreasson JO, Grimes KV, Frumkin LR, Sanjines E, Davidson MG, Park KT, Limketkai B. Treatment-refractory ulcerative colitis responsive to indigo naturalis. BMJ Open Gastroenterol. 2021 Dec;8(1):e000813. doi: 10.1136/bmjgast-2021-000813.

Reference Type: DERIVED

PMID: 34969665 (View on PubMed)

Other Identifiers

30934

Identifier Type: -

Identifier Source: org_study_id